Table 2

Likelihood of non-adherence by oral anticoagulant

nUnivariable
OR (95% CI)
Multivariable
OR (95% CI)
P value
33 96031 615
VKA1.00 (–)1.00 (–)
Dabigatran0.53 (0.47 to 0.60)0.54 (0.48 to 0.62)<0.001
Rivaroxaban0.61 (0.58 to 0.65)0.76 (0.71 to 0.82)
Apixaban0.57 (0.54 to 0.61)0.77 (0.71 to 0.84)
CHA2DS2VASc
 0–11.00 (–)
 21.00 (0.93 to 1.08)<0.001
 3–40.94 (0.88 to 1.01)
 5–90.81 (0.74 to 0.89)
HASBLED-1
 0–21.00 (–)
 3–90.98 (0.93 to 1.05)0.62
Number of drugs
Continuous/Linear0.99 (0.98 to 1.00)0.067
Townsend quintile
 11.00 (–)
 20.93 (0.87 to 0.99)<0.001
 30.86 (0.80 to 0.91)
 40.91 (0.85 to 0.97)
 50.86 (0.80 to 0.94)
Date of first prescription* (years after 1 January 2011)
Continuous/Linear1.29 (1.22 to 1.37)<0.001
Continuous/Quadratic0.94 (0.93 to 0.95)
BIC46 263.6342 880.41
  • *Time difference (in years) between the date of the first ever OAC prescription for each patient and the start date of the study (1 January 2011). This suggests that the maximum effect of calendar time occurs at −ln(1.29)(2×/ln(0.94))=2.13 years.

  • BIC, Bayes information criterion; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65-74 years, Sex category ; HASBLED-1, Hypertension; Abnormal renal/liver function; Stroke; Bleeding; Labile INR; Elderly; Drugs or alcohol; OAC, oral anticoagulant; VKA, vitamin K antagonist.